Singapore markets closed

Novo Nordisk A/S (NVO)

NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
107.08+0.44 (+0.41%)
At close: 04:00PM EST
107.61 +0.53 (+0.49%)
After hours: 06:22PM EST
Full screen
Trade prices are not sourced from all markets
Previous close106.64
Open109.27
Bid104.92 x 1100
Ask109.38 x 1300
Day's range106.06 - 109.43
52-week range66.59 - 115.95
Volume759,532
Avg. volume876,738
Market cap248.419B
Beta (5Y monthly)N/A
PE ratio (TTM)35.21
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Zacks

    GSK vs. NVO: Which Stock Should Value Investors Buy Now?

    GSK vs. NVO: Which Stock Is the Better Value Option?

  • Reuters

    Novo Nordisk says lower insulin prices in China dent 2022 outlook

    Novo Nordisk on Friday forecast its sales growth would slow by about 3% in 2022 because of lower prices and a drop in insulin sales volumes in China, denting the Danish diabetes drug maker's share price. The forecast comes after Novo received results from China's Volume Based Procurement (VBP) tender, which covers insulin sold at Chinese hospitals. "Novo Nordisk currently expects an estimated negative impact on global sales growth of around 3% in 2022 as a result of reduced prices and reduced volumes of insulin sold in China," it said in a statement.

  • Motley Fool

    4 Reasons Arrowhead Pharmaceuticals Could Be the Next Biotech Buyout

    The recent acquisition of Dicerna Pharmaceuticals makes Arrowhead Pharmaceuticals look like the next biotech in line to receive a juicy buyout offer.